Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of Orion B shares owned by the mutual funds under the management of Capital Research and Management Company, has on 22 September 2011 through trades in the course of ordinary business exceeded the one twentieth (1/20) threshold of the total number of Orion Corporation shares.
The holding of the mutual funds under the management of Capital Research and Management Company according to the disclosure:
| Share type | Number of shares | Percent (%) of total shares | Percent (%) voting rights |
| A share | 0 | 0 | 0 |
| B share ISIN:FI0009014377 | 7,196,174 | 5.0944 | 0.7135 |
| Total | 7,196,174 | 5.0944 | 0.7135 |
After the acquisition mentioned in the notification total 400,000 Orion Corporation A-shares have been converted into 400,000 B-shares. After that the total share of the voting rights of the mutual funds under the management of Capital Research and Management Company is 0.7189. per cent.
The taxpayer I.D. advised by Capital Research and Management Company: 95-1411037. Additional information about the company: www.capgroup.com.
Orion Corporation's share capital comprises 141.257.828 shares, of which 45.247.646 are A shares and 96.010.182 are B shares. Each A share entitles its holder to twenty (20) votes and each B share to one (1) vote. Thus, the total number of votes is 1.000.963.102.
Orion Corporation
| Timo Lappalainen President and CEO | Olli Huotari SVP, Corporate Functions |
Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.